GlaxoSmithKline to announce ability to produce bird flu vaccine

Share this article:

British drug maker GlaxoSmithKline is set to announce it would be able to produce millions of doses of a vaccine against avian (bird) flu, within four months of declaration of a pandemic.                        A vaccine could not be produced any sooner because scientists would need to know the exact strain of the flu before formulating an inoculation.
The firm will make the announcement on Thursday when it presents its quarterly results, a report in the U.K.'s Sunday Times said.
Plans to purchase enough vaccine to cover every person in the U.K. have been set in motion -- 120 million doses, or two doses for each person there -- in the event of a flu pandemic.
Meanwhile, the FDA has announced the formation of a rapid response team to ensure that enough legitimate antiviral drugs are available to the American public, in the event of an avian flu pandemic.
"Using the rapid response team approach, we believe we could review a complete drug application in six to eight weeks," said Andrew von Eschenbach, acting FDA commissioner. 
The team was also formed to help combat the counterfeiting of bird flu-fighting drugs, including Roche's Tamiflu (oseltamivir phosphate).
"We have begun to have some concern that there may be a threat of counterfeiting with respect to Tamiflu," Health and Human Services secretary Michael Leavitt told reporters in a telephone briefing.
Tamiflu, and GlaxoSmithKline's Relenza (zanamivir) are known to work against the virus. And there is evidence that another older influenza drug called rimantadine may also work. None of the treatments cure influenza. However, they may be prescribed to reduce the impact of the virus.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...